deferasirox

01/01/2012 - "We report two patients who achieved a marked improvement of hematopoiesis with the use of deferasirox (DSX) for transfusional iron overload. "
12/01/2013 - "Efficacy of Deferasirox for the treatment of iron overload in Chinese thalassaemia major patients: results from a prospective, open-label, multicentre clinical trial."
05/01/2012 - "In conclusion, our data suggest that oral deferasirox treatment may be used as a safe and effective alternative method for reducing iron overload in alloHSCT recipients, whether combined with or without phlebotomy."
06/01/2010 - "Although the number of subjects is small, deferasirox may be a safe and effective alternative for allogeneic HCT survivors with iron overload who cannot undergo phlebotomy."
07/01/2013 - "In this review, we report the results of different studies testing safety and efficacy of deferasirox in MDS patients, side effects associated with the drug, and suggested management of iron overload."

06/01/2012 - "Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major."
05/01/2006 - "A comparative phase 3 trial was conducted to demonstrate the efficacy of deferasirox in regularly transfused patients with beta-thalassemia aged 2 years or older. "
01/01/2012 - "Efficacy of deferasirox in North Indian β-thalassemia major patients: a preliminary report."
03/01/2013 - "This study aimed to estimate the incidence of deferasirox (DFX) side effects in patients with thalassemia major or intermedia. "
04/15/2012 - "The method can be used to support a wide range of clinical studies concerning deferasirox monitoring and it was applied to the analysis of human plasma samples obtained from patients with β-thalassemia major."

08/01/2014 - "Efficacy of deferasirox in children with β-thalassemia: single-center 3 year experience."
01/01/2012 - "HRQOL improved following treatment with deferasirox, particularly among β-thalassemia patients. "
10/01/2011 - "Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years."
03/01/2011 - "Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia."
12/01/2015 - "The aim of this study was to evaluate the long-term efficacy and tolerability of deferasirox in Taiwanese patients with transfusion-dependent β-thalassemia who have been treated with deferasirox for 7 years. "

04/01/2013 - "Safety and efficacy of deferasirox in the management of transfusion-dependent patients with myelodysplastic syndrome and aplastic anaemia: a perspective review."
09/01/2012 - "This analysis suggests that deferasirox treatment for up to 1 year could lead to improvement in hematologic parameters in some patients with myelodysplastic syndromes."
06/10/2012 - "This 3-year, prospective, multicenter trial assessed the safety and efficacy of deferasirox in low- or intermediate-1-risk myelodysplastic syndrome (MDS). "
06/01/2014 - "Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial)."
04/01/2015 - "A case of transfusion independence in a patient with myelodysplastic syndrome using deferasirox, sustained for two years after stopping therapy."

01/01/2013 - "Here, we describe the case of a 73-year-old man affected by PMF and severe transfusion-dependent anemia who experienced a dramatic erythroid response after being treated with deferasirox to prevent IOL. "
01/01/2009 - "Cumulative data from prospective studies in over 3,000 patients with a range of transfusion dependent anemias have established key principles about the efficacy and safety of deferasirox (DFS). "
06/01/2007 - "The efficacy and safety of deferasirox have been established in a comprehensive clinical development program involving patients with various transfusion-dependent anemias. "
09/23/2015 - "Acute Liver Failure in a Pediatric Patient with Congenital Dysery-Thropoietic Anemia Type I Treated with Deferasirox."
04/01/2015 - "We analyzed deferasirox plasma concentrations (CDFX ) in 80 patients with transfusion-dependent anemias, such as thalassemia, by a high performance liquid chromatography (HPLC) assay. "